255 related articles for article (PubMed ID: 7900703)
21. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.
Aranda E; Díaz-Rubio E; Cervantes A; Antón-Torres A; Carrato A; Massutí T; Tabernero JM; Sastre J; Trés A; Aparicio J; López-Vega JM; Barneto I; García-Conde J
Ann Oncol; 1998 Jul; 9(7):727-31. PubMed ID: 9739438
[TBL] [Abstract][Full Text] [Related]
22. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
23. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
Valone FH; Friedman MA; Wittlinger PS; Drakes T; Eisenberg PD; Malec M; Hannigan JF; Brown BW
J Clin Oncol; 1989 Oct; 7(10):1427-36. PubMed ID: 2789272
[TBL] [Abstract][Full Text] [Related]
24. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R
Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
O'Byrne KJ; Philip PA; Propper DJ; Braybrooke JP; Saunders MP; Bates NP; Taylor MA; Madigan D; Ganesan TS; Talbot DC; Harris AL
Ann Oncol; 1999 Aug; 10(8):981-3. PubMed ID: 10509162
[TBL] [Abstract][Full Text] [Related]
26. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Hofheinz R; Hartung G; Samel S; Emig M; Pilz L; Willeke F; Hochhaus A; Hehlmann R; Queisser W
Anticancer Drugs; 2002 Nov; 13(10):999-1004. PubMed ID: 12439333
[TBL] [Abstract][Full Text] [Related]
27. Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study.
Moehler M; Gutzler F; Steinmann S; Boehme M; Raeth U; Stremmel W; Galle PR; Rudi J
Chemotherapy; 2003 May; 49(1-2):85-9. PubMed ID: 12714817
[TBL] [Abstract][Full Text] [Related]
28. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
29. A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Kalofonos HP; Nicolaides C; Samantas E; Mylonakis N; Aravantinos G; Dimopoulos MA; Gennatas C; Kouvatseas G; Giannoulis E; Dervenis C; Basdanis G; Pavlidis N; Androulakis I; Fountzilas G;
Am J Clin Oncol; 2002 Feb; 25(1):23-30. PubMed ID: 11823690
[TBL] [Abstract][Full Text] [Related]
30. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
[TBL] [Abstract][Full Text] [Related]
31. Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial.
Adler S; Lang S; Langenmayer I; Eibl-Eibesfeldt B; Rump W; Emmerich B; Hallek M
Cancer; 1994 Jun; 73(12):2905-12. PubMed ID: 8199987
[TBL] [Abstract][Full Text] [Related]
32. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
Poon MA; O'Connell MJ; Moertel CG; Wieand HS; Cullinan SA; Everson LK; Krook JE; Mailliard JA; Laurie JA; Tschetter LK
J Clin Oncol; 1989 Oct; 7(10):1407-18. PubMed ID: 2476530
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Graeven U; Ridwelski K; Artandi M; Espana P; Schölmerich J; Rosales AM; Carlsson G; Borner M; Boussard B; Schmiegel W
Oncol Rep; 2005 Apr; 13(4):681-8. PubMed ID: 15756442
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer.
Jones DV; Winn RJ; Brown BW; Levy LB; Pugh RP; Wade JL; Gross HM; Pendergrass KB; Levin B; Abbruzzese JL
Cancer; 1995 Nov; 76(10):1709-14. PubMed ID: 8625038
[TBL] [Abstract][Full Text] [Related]
37. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
[TBL] [Abstract][Full Text] [Related]
38. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Köhne CH; Hiddemann W; Schüller J; Weiss J; Lohrmann HP; Schmitz-Hübner U; Bodenstein H; Schöber C; Wilke H; Grem J
J Clin Oncol; 1995 May; 13(5):1201-8. PubMed ID: 7738622
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.
Comella P; Massidda B; Filippelli G; Palmeri S; Natale D; Farris A; De Vita F; Buzzi F; Tafuto S; Maiorino L; Mancarella S; Leo S; Lorusso V; De Lucia L; Roselli M
Ann Oncol; 2005 Jun; 16(6):878-86. PubMed ID: 15837702
[TBL] [Abstract][Full Text] [Related]
40. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]